drugset / Trial / NCT06855212
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
Phase 2
Active not recruiting
22 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Eli Lilly and Company · collabRegeneron Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to determine if cemiplimab in combination with cetuximab given before their surgery are beneficial and safe in participants with head and neck squamous cell carcinoma (HNSCC).
Timeline
- Start
- 2025-02-26
- Primary completion
- 2028-03
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |